Clinical trials: CtDNA
Relapsed/Refractory Large B-cell Lymphoma
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post…
- Trial name
- EpLCART (NCT06414148)
- Testing
- Epcoritamab, Epcoritamab, lenalidomide and rituximab
- Where
- 6 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Colorectal Cancer Metastatic
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
Following systemic therapy in metastatic colorectal cancer(mCRC),RAS (including KRAS, NRAS and HRAS gene) status may change from a mutant(MT) to a wild-type(WT),a phenomenon known as "NeoRAS WT"mCRC.NeoRAS WT can be detected by…
- Trial name
- NCT06440902
- Testing
- Cetuximab
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Fudan University
Colorectal Cancer
A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood
This multi-center study aims to develop a precise predictive model for colorectal cancer (CRC) recurrence and metastasis based on multi-omics analysis of portal vein blood.
- Trial name
- PVMRD (NCT06524245)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Peking University Shougang Hospital
Advanced Colorectal Cancer, Circulating Tumor DNA
Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules
The clinical diagnosis and treatment of small pulmonary nodules (suspected to be lung metastases) in advanced colorectal cancer patients remain controversy.
- Trial name
- NCT05495672
- Testing
- Local treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Junjie Peng
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Prospective ctDNA Testing in Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) are aggressive lymphomas commonly treated with first-line immunochemotherapy. Some patients experience disease progression or relapse despite treatment.
- Trial name
- NCT07878351
- Testing
- Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such as R-CHOP, Pola-R-CHP, or DA-EPOCH-R.
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return.
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
- Trial name
- NCT04585477
- Testing
- AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Stanford University
Pancreatic Cancer
Personalized Precision Diagnosis and Treatment of Pancreatic Cancer
Pancreatic cancer (PC) is the 4th common cancer in the world and occupied the second place for digestive tumors, of which the incidence has also increased sharply in China.
- Trial name
- PPDTPC (NCT04373928)
- Testing
- Drug guided by Mini-PDX/PDX
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changhai Hospital
Carcinoma, Non-Small-Cell Lung
Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA
Circulating tumor DNA (ctDNA) is a highly specific and effective biomarker for the detection of EGFR mutation status. We hypothesise AZD9291 is efficacious in patients with EGFR sensitizing mutations and T790M detected in plasma…
- Trial name
- PLASMA (NCT02811354)
- Testing
- AZD9291
- Where
- 8 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 108 people
- Sponsor
- National University Hospital, Singapore
Oropharynx Squamous Cell Carcinoma
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
SURVEILLE-HPV - A new post therapeutic surveillance strategy for HPV-driven oropharyngeal cancer based on HPV Circulating DNA measures.
- Trial name
- SURVEILLE-HPV (NCT05582122)
- Testing
- HPV16 Ct-DNA dosing
- Where
- 16 sites in France
- Volunteers
- 420 people
- Sponsor
- UNICANCER
Non-small Cell Lung Cancer, ALK-Positive Lung Cancer
Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC
The investigators plan to understand a comprehensive molecular profiling via the plasma, with the primary aim of using this form on analysis to guide subsequent treatment selection.
- Trial name
- NCT04087473
- Where
- 5 sites in Hong Kong, Malaysia and 2 more
- Volunteers
- 50 people
- Sponsor
- National Cancer Centre, Singapore
Solid Tumor, Adult
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. 2.
- Trial name
- NCT03302325
- Testing
- research blood draws
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Appendix Carcinoma by AJCC V8 Stage, Colorectal Carcinoma by AJCC V8 Stage
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
This clinical trial collects biospecimen samples to create a personalized ctDNA test to guide treatment for patients with gastrointestinal cancer with peritoneal carcinomatosis.
- Conditions
- Appendix Carcinoma by AJCC V8 Stage, Colorectal Carcinoma by AJCC V8 Stage, Digestive System Neoplasm, Esophageal Carcinoma by AJCC V8 Stage
- Trial name
- NCT04929015
- Testing
- Biospecimen Collection - blood and tissue sample collection, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey
Choroidal Melanoma, Diffuse
Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma
Circulating tumor DNA detection and quantification in patients with metastatic choroidal melanoma.
- Trial name
- NCT01334008
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut Curie
Lung Diseases, Lung Cancer Screening
Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer
This is an observational clinical trial, aiming to evaluate the efficacy of the SPOTMAS LUNG (SML) test compared to Low dose CTScan (LDCT)/None contrast CTScan (NCCT) in two distinct risk populations: Cohort A: To demonstrate…
- Trial name
- NCT07126626
- Where
- Vietnam
- Volunteers
- 1,184 people
- Sponsor
- Gene Solutions
Esophageal Squamous Cell Carcinoma
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
- Trial name
- NCT05426850
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Peritoneal Carcinomatosis
Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Under PIPAC
PIPADN is a pilot monocentric, study with a total duration of 42 months. The purpose of this study is to describe the variation of plasma ctDNA concentration between the 1st and the 3rd PIPAC session in patients with peritoneal…
- Trial name
- PIPADN (NCT04766502)
- Testing
- Blood sample (20 ml) and EORTC QLQC30 survey
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut de Cancérologie de Lorraine
Leiomyoma, Leiomyosarcoma
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
The development of an accurate and non-invasive diagnostic method is a priority in areas such as gynecology and oncology, specifically to improve the health of those patients with surgical indication for diagnosis of myometrial…
- Trial name
- MYOSARC (NCT04214457)
- Testing
- Biopsy and peripheral blood collection
- Where
- 4 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- Igenomix
Non-small Cell Lung Cancer
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
- Trial name
- NCT03791034
- Where
- South Korea
- Volunteers
- 700 people
- Sponsor
- Samsung Medical Center
Colon Adenocarcinoma, High-Frequency Microsatellite Instability
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other…
- Conditions
- Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma
- Trial name
- NCT03436563
- Testing
- Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Gastric (Stomach) Cancer
Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers
This is a single blind, case control, multicenter study jointly developed by Zhongshan Hospital of Fudan University, Shanghai Public Health Clinical Center, Shanghai Xuhui Central Hospital, Qingpu Branch of Zhongshan Hospital…
- Conditions
- Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05431621
- Where
- 4 sites in China
- Volunteers
- 2,430 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital